Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)147.65K

Market Cap

¥10.33B

Enterprise Value¥8.23K

Total Cash (Recent Filing)¥907.94M

Total Debt (Recent Filing)¥171.81M

Price to Earnings (P/E)28.0

Beta0.91

Next Earnings

Oct 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.54%

Share Statistics

EPS (TTM)39.54

Shares Outstanding9,314,590

10 Day Avg. Volume166,350

30 Day Avg. Volume147,646

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong ProfitabilityThe latest results show strong economics across gross, operating, and net profit levels, indicating meaningful earnings power from the company’s core activities. If these margins remain supported by product demand, they can fund research investment, strengthen resilience, and support recurring profitability.

Conservative Balance SheetLow leverage and rising equity give the company financial flexibility as it builds on its earnings recovery. Reduced debt dependence limits financing pressure, while improved returns on equity indicate that capital is being used more productively than during the earlier loss-making period.

Recurring Reagent ModelResearch reagents and assay products are consumables used within ongoing laboratory workflows, creating the potential for repeat purchases rather than relying solely on infrequent transactions. Continued research activity and replenishment needs can provide a durable base for customer retention and revenue generation.

Bears Say

Profitability VolatilityThe recent turnaround is encouraging, but the sharp swing from substantial losses to strong profits shows that earnings have not yet demonstrated a long, stable record. This history raises the risk that current margins could weaken if operating conditions or product demand become less favorable.

Uneven Cash ConversionStrong 2026 operating and free cash flow improves the company’s financial position, but prior inconsistency indicates that accounting profits have not always translated reliably into cash. Uneven conversion can constrain internally funded investment and makes the durability of the latest recovery more important.

Moderate Revenue ExpansionRevenue growth remains positive, yet the latest annual increase was relatively moderate compared with the strength of reported margins and earnings. Slower top-line expansion could limit operating leverage and make future profit performance more dependent on maintaining margins rather than broadening the revenue base.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥10.33B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 46 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on Aug 07, 2026. The company reported ¥10.76 earnings per share for the quarter.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Annually dividend of ¥7.5 which represents an annual dividend yield of 0.54%. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥10.76 in its last earnings report. Following the earnings report the stock price went down -1.261%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.